The safety and efficacy of cannabis-based products depend on an integrated chain involving chemists, biomedicals, pharmacists, and doctors — professionals who ensure, at each stage, the quality, stability, and trust in patient treatment

Episode addresses the update of RDC 660, international certification, and challenges to expand access to treatments with different cannabinoids in Brazil.

Measure comes as the state government pressures the Legislature to include new diseases in the program

Director of Institutional Relations evaluates national cultivation, new RDCs from Anvisa, and the challenges to consolidate the sector in the country

Survey of adult cannabis users indicates a decrease in weekly alcohol consumption after adopting cannabis-infused beverages

Political representatives of health and public safety in South Africa point to an increase in illegal offers and misuse of licenses in accessing medicinal cannabis

Decision by the European Union Court of Justice states the country violated bloc rules by independently voting on the plant

Revision of RDC 327 allows the compounding sector to produce derivatives, while individual importation by individuals remains under old rules and will be analyzed separately

Proposal authorizes companies to cultivate plants with up to 0.3% THC exclusively for the production of medicinal inputs, but experts warn of the technical unfeasibility of the limit in a tropical climate

Scientific Committee maintains technical rigor and focuses on a forward-looking program in the 5th edition of the event in São Paulo

Research published in Sleep Medicine: X reveals that the herbal remedy improves sleep quality and quality of life with safety similar to benzodiazepines

Botswana has published new rules for cannabis, with THC limits, strict licenses, and control over cultivation, transportation, research, and export

Event opens deadline for submission of scientific abstracts in oral presentation and poster formats

The National Narcotics Fund (FNE) will no longer require Export Certificates for shipments destined to patients (Individuals) in Brazil, eliminating a bureaucratic obstacle that hindered the flow of derivatives between the two countries

Resumption of review by Anvisa and final deadline from STJ for cultivation define the sector's direction in the first quarter of the year

Adesaf Institute points out unconstitutionality in vetoing workers with a criminal history in research areas and requests a review of the measure

Study analyzed Cannabis sativa extracts rich in CBC and THC and observed cytotoxic effects on human urothelial carcinoma cells and tissues

Federal reclassification drives mergers and acquisitions in the US cannabis sector

Ministry of Health extends deadline to avoid treatment interruptions in 2026; industry demands permanent law already validated by the EU

National mobilization seeks to maintain Anvisa's RDC 660/2022 and avoid risks to the continuity of treatments for thousands of patients